What is the future of CCR5 antagonists in rheumatoid arthritis?

Tsutomu Takeuchi, Hideto Kameda

Research output: Contribution to journalEditorialpeer-review

7 Citations (Scopus)

Abstract

Fleishaker and colleagues reported on a double-blind placebo controlled clinical trial of a C-C chemokine-receptor type 5 (CCR5) antagonist, maraviroc, in rheumatoid arthritis (RA) patients with inadequate response to methotrexate, showing that it was ineffective. Two additional CCR5 antagonists, SCH351125 and AZD5672, also failed to demonstrate clinical efficacy. In addition, CCR5-blocking antibodies could not inhibit synovial fluid-induced monocyte chemotaxis. Thus, CCR5 appears not to be a desirable target in RA treatment. Given the multiple functions of CCR5, redundancies in the chemokine system, and patient selection in the trial, we overview the recent understanding for chemokine receptor blockade in the treatment of RA.

Original languageEnglish
Article number114
JournalArthritis Research and Therapy
Volume14
Issue number2
DOIs
Publication statusPublished - 2012 Mar 30

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'What is the future of CCR5 antagonists in rheumatoid arthritis?'. Together they form a unique fingerprint.

Cite this